Form SCHEDULE 13D MAXCYTE, INC. Filed by: Liontrust Investment Partners LLP

Thu, 15 Oct 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20261015/27190663.html

MaxCyte stock surges 25% on raised 2026 revenue guidance

Wed, 14 Oct 2026 12:25:12 -0400

Investing.com -- MaxCyte Inc (NASDAQ:MXCT) shares jumped 25% Wednesday after the cell-engineering company raised its full-year 2026 revenue guidance following strong third-quarter results.

The company reported preliminary third-quarter core business revenue of approximately $8.1 million, up 26% YoY from the third quarter of 2025 and exceeding the analyst estimate of $7.02 million. MaxCyte also recorded Strategic Platform License Program-related revenue of more than $1.0 million, including a $1.0 million milestone payment received during the quarter.

MaxCyte raised its full-year 2026 revenue guidance to approximately $34 million from prior guidance of $30 million to $32 million, surpassing the analyst estimate

MaxCyte stock surges 25% on raised 2026 revenue guidance

Wed, 14 Oct 2026 12:25:12 -0400

Investing.com -- MaxCyte Inc (NASDAQ:MXCT) shares jumped 25% Wednesday after the cell-engineering company raised its full-year 2026 revenue guidance following strong third-quarter results.

MaxCyte raised its full-year 2026 revenue guidance to approximately $34 million from prior guidance of $30 million to $32 million, surpassing the analyst estimate

Form 8-K MAXCYTE, INC. For: Oct 14

Wed, 14 Oct 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20261014/27184150.html

MaxCyte raises 2026 revenue guidance after strong Q3 results

Wed, 14 Oct 2026 08:06:13 -0400

MaxCyte, Inc. (NASDAQ: MXCT) reported preliminary third-quarter 2026 core business revenue of approximately $8.1 million, a 26% increase compared to the same period in 2025, according to a company statement.

The Rockville, Md.-based cell-engineering company also reported Strategic Platform License (SPL) Program-related revenue of more than $1.0 million for the quarter, which includes a $1.0 million milestone payment. Royalty revenue will be reported with full financial results on November 10, 2026.

MaxCyte raised its full-year 2026 revenue guidance to approximately $34 million, up from prior guidance of $30 million to $32 million. The updated outlook includes core business revenue of approximately $28

MaxCyte raises 2026 revenue guidance after strong Q3 results

Wed, 14 Oct 2026 08:06:13 -0400

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

Wed, 14 Oct 2026 08:05:00 -0400

MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026

ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance.

Preliminary Third Quarter Revenue

Core business revenue of approximately $8.1 million in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025.
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

Wed, 14 Oct 2026 08:05:00 -0400

MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026
ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced preliminary revenue for the third quarter ended September 30, 2026 and raised its 2026 revenue guidance.

Preliminary Third Quarter Revenue
- Core business revenue of approximately $8.1 million in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025.
- MaxCyte names Sidharth Kapileshwar as chief corporate development officer
  
  Wed, 23 Sep 2026 08:05:26 -0400
  
  MaxCyte, Inc. (Nasdaq: MXCT) has appointed Sidharth Kapileshwar as Chief Corporate Development Officer, the Rockville, Md.-based cell engineering company announced.
  Kapileshwar joins MaxCyte from Danaher Corporation, where he most recently served as Vice President of Innovation for the company's Life Sciences Platform. Over nearly 25 years, he has held corporate development, strategy, innovation, and M&A leadership roles at GE Healthcare, Beckman Coulter, and Halma plc.
  Kapileshwar holds a Master of Science in Engineering from The Ohio State University, an MBA from the University of Chicago Booth School of Business, and a Bachelor of Technology in Engineering from the Indian Institute of Technology
  
  MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
  
  Wed, 23 Sep 2026 08:05:00 -0400
  
  ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer.
  
  "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the world. He knows firsthand what it takes to translate strategy into growth,” said Maher Masoud, President and Chief Executive Officer. “I am confident that Sidharth’s expertise will support MaxCyte’s next
  
  MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
  
  Wed, 23 Sep 2026 08:05:00 -0400
  
  ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer.
  
  "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the world. He knows firsthand what it takes to translate strategy into growth,” said Maher Masoud, President and Chief Executive Officer. “I am confident that Sidharth’s expertise will support MaxCyte’s next
  
  MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  
  Fri, 11 Sep 2026 16:30:00 -0400
  
  ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte’s common stock and a service-based restricted stock unit (“RSU”) award with respect to 110,000 shares of MaxCyte’s common stock to Sidharth Kapileshwar, in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development
  
  MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  
  Fri, 11 Sep 2026 16:30:00 -0400
  
  ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that the Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 220,000 shares of MaxCyte’s common stock and a service-based restricted stock unit (“RSU”) award with respect to 110,000 shares of MaxCyte’s common stock to Sidharth Kapileshwar, in connection with his commencement of employment as Senior Vice-President, Chief Corporate Development
  
  BTIG Reiterates Neutral Rating on MaxCyte Inc. (MXCT)
  
  Mon, 24 Aug 2026 06:17:52 -0400
  
  BTIG analyst Mark Massaro reiterated a Neutral rating on MaxCyte Inc. (NASDAQ: MXCT).
  The analyst commented: "In this note, we update our MXCT model following the company's Q2'26 earnings print. MXCT did deliver a slight Q2 beat relative to consensus though reaffirmed its 2026 revenue outlook. MXCT is energized by its recent multi-platform technology license deal signed with Genentech (Roche [RHHBY, Not Rated]) to support multiple cell therapy programs across research, clinical development and manufacturing workflows. Under the agreement, Genentech will gain access to MXCT's ExPERT GTx platform and additional platform technologies that support ex vivo cell engineering applications. This partnership
  
  MaxCyte adds two off-target assays for base editor genome therapies
  
  Wed, 19 Aug 2026 08:06:05 -0400
  
  MaxCyte, Inc. (NASDAQ: MXCT) announced the launch of two off-target nomination assays, CHANGE-seq-BE and ONE-seq-BE, designed for use in genome editing therapy development, according to a company press release.
  The assays are available through MaxCyte's SeQure service and target adenine and cytosine base editors (ABEs and CBEs). CHANGE-seq-BE is described as a biochemical off-target nomination method for base editors, while ONE-seq-BE is characterized as the only nomination assay for base editors that provides visibility of population-specific genetic variants that may affect off-target activity.
  Together, the two assays are intended to give therapeutic developers access to orthogonal nomination methods from a single provider.
  
  MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
  
  Wed, 19 Aug 2026 08:05:00 -0400
  
  ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte’s SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs).
  
  SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and
  
  MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
  
  Wed, 19 Aug 2026 08:05:00 -0400
  
  ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of the CHANGE-seq-BE™ and ONE-seq-BE™ off-target nomination assays. Available through MaxCyte’s SeQure™ service, these assays address a key gap in genome editing characterization by offering sensitive nomination of off-target sites for adenine and cytosine base editors (ABEs and CBEs).
  
  SeQure provides integrated reporting across orthogonal nomination assays, enabling therapeutic developers to identify overlapping and distinct nominated sites and
  
  Form 10-Q MAXCYTE, INC. For: Jun 30
  
  Thu, 13 Aug 2026 16:33:00 -0400
  si-local-file:///var/storage/secattach/20260813/26921964.html
  
  Form 10-Q MAXCYTE, INC. For: Jun 30
  
  Thu, 13 Aug 2026 16:33:00 -0400
  si-local-file:///var/storage/secattach/20260813/26921964.html
  
  MaxCyte, Inc. (MXCT) Reports In-Line Q2 EPS
  
  Wed, 12 Aug 2026 17:09:37 -0400
  
  MaxCyte, Inc. (NASDAQ: MXCT) reported Q2 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $7.27 million versus the consensus estimate of $6.63 million.
  For earnings history and earnings-related data on MaxCyte, Inc. (MXCT) click here.
  
  Form 8-K MAXCYTE, INC. For: Aug 12
  
  Wed, 12 Aug 2026 16:15:00 -0400
  si-local-file:///var/storage/secattach/20260812/26913066.html
  
  Form 8-K MAXCYTE, INC. For: Aug 12
  
  Wed, 12 Aug 2026 16:15:00 -0400
  si-local-file:///var/storage/secattach/20260812/26913066.html
  MaxCyte Reports Second Quarter 2026 Financial Results
  
  Wed, 12 Aug 2026 16:05:00 -0400
  - Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue
  - Reiterates Full Year 2026 Guidance
  - Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the Board
  - Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July
  ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
  MaxCyte Reports Second Quarter 2026 Financial Results
  
  Wed, 12 Aug 2026 16:05:00 -0400
  - Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue
  - Reiterates Full Year 2026 Guidance
  - Repurchased approximately $5.5 million of common stock to date under the Company’s $10 million share repurchase program authorized by the Board
  - Following end of quarter, announced strategic, multi-platform technology license partnership with Genentech in July
  ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
  Form SCHEDULE 13D MAXCYTE, INC. Filed by: RIVER GLOBAL INVESTORS LLP
  
  Tue, 04 Aug 2026 08:43:00 -0400
  si-local-file:///var/storage/secattach/20260804/26862515.html

StreetInsider.com News Articles

Form SCHEDULE 13D MAXCYTE, INC. Filed by: Liontrust Investment Partners LLP

MaxCyte stock surges 25% on raised 2026 revenue guidance

MaxCyte stock surges 25% on raised 2026 revenue guidance

Form 8-K MAXCYTE, INC. For: Oct 14

MaxCyte raises 2026 revenue guidance after strong Q3 results

MaxCyte raises 2026 revenue guidance after strong Q3 results

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance

MaxCyte names Sidharth Kapileshwar as chief corporate development officer

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BTIG Reiterates Neutral Rating on MaxCyte Inc. (MXCT)

MaxCyte adds two off-target assays for base editor genome therapies

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

Form 10-Q MAXCYTE, INC. For: Jun 30

Form 10-Q MAXCYTE, INC. For: Jun 30

MaxCyte, Inc. (MXCT) Reports In-Line Q2 EPS

Form 8-K MAXCYTE, INC. For: Aug 12

Form 8-K MAXCYTE, INC. For: Aug 12

MaxCyte Reports Second Quarter 2026 Financial Results

MaxCyte Reports Second Quarter 2026 Financial Results

Form SCHEDULE 13D MAXCYTE, INC. Filed by: RIVER GLOBAL INVESTORS LLP